Yes, Alzheimer’s risk scores can be misused, and this happens in several documented ways. These predictive tools—which calculate someone’s likelihood of developing Alzheimer’s disease based on genetics, biomarkers, and lifestyle factors—are increasingly available to consumers and healthcare providers, but they’re frequently misinterpreted, misapplied, or weaponized in ways that cause real harm. A person who receives a high-risk score might face insurance discrimination, employment bias, or severe psychological distress, even though that score cannot predict whether they’ll actually develop disease in their lifetime. The misuse stems from a fundamental mismatch between what risk scores actually measure and how people use them.
A genetic risk score showing elevated vulnerability is not a diagnosis. It’s not a guarantee. Yet patients, insurers, employers, and even some clinicians treat these probabilities as certainties or use them to deny services, employment, or coverage. The damage is compounded because most risk scores are built on populations that don’t reflect all ethnic backgrounds, making predictions less accurate for people of color.
Table of Contents
- How Are Alzheimer’s Risk Scores Actually Being Misused in Practice?
- Why Are These Scores Being Misinterpreted, and What’s at Stake?
- What Role Do Commercial Tests and Marketing Play in Misuse?
- How Can Patients and Clinicians Use Risk Scores Responsibly?
- What Are the Known Harms of False Positives and Psychological Burden?
- How Do Equity and Access Issues Amplify Misuse?
- Where Are Safeguards Failing, and What Needs to Change?
How Are Alzheimer’s Risk Scores Actually Being Misused in Practice?
alzheimer‘s risk scores are misused primarily through three mechanisms: insurance and employment discrimination, psychological weaponization, and clinical overreach. Insurance companies have already begun requesting genetic testing and using risk scores to deny coverage, rescind policies, or charge premiums based on a prediction that may never materialize. In 2023 and 2024, disability and life insurance companies began asking applicants for genetic risk data, and several cases emerged where high polygenic risk scores triggered policy denials despite no diagnosis.
An individual with a high APOE4 score—a common genetic marker linked to Alzheimer’s—can be denied disability coverage even though 30% of people without the disease also carry this gene. Employers are beginning to screen candidates’ genetic risk profiles before hiring, a practice that violates the intent of the Genetic Information Nondiscrimination Act (GINA) in many cases, even if the letter of the law hasn’t caught up. A person identified as high-risk for Alzheimer’s at age 35 may be passed over for demanding roles or excluded from professional development programs because employers fear reduced productivity or future healthcare costs. This happens without any current cognitive decline or diagnosis, based solely on statistical probability.
Why Are These Scores Being Misinterpreted, and What’s at Stake?
Risk scores are fundamentally probabilistic, yet they’re routinely treated as diagnostic or deterministic. A composite Alzheimer’s risk score might say “60% chance of cognitive impairment by age 85,” but this is presented to patients as “you will develop Alzheimer’s” or “you are likely to become demented.” The psychological burden is severe. Studies have shown that receiving a high-risk score increases anxiety, depression, and health-related stress in people with no cognitive symptoms.
Some begin unnecessary treatments, restrict their lives, or spiral into “healthy hypochondria.” The score’s limitations are rarely explained. Most Alzheimer’s risk models were built using predominantly European ancestry populations, so predictions are markedly less accurate for African Americans, Hispanics, and Asian populations. A Black patient receiving a risk score trained on 80% European genomes is getting a tool that has never been validated in their population, yet it’s presented with the same authority. Additionally, many risk scores ignore modifiable factors (cognitive reserve, social engagement, physical fitness, diet) and overweight genetics, leading clinicians and patients to fatalism: “My genes are against me, so why try lifestyle changes?”.
What Role Do Commercial Tests and Marketing Play in Misuse?
Direct-to-consumer Alzheimer’s risk tests have proliferated in the past three years, often marketed with language that exaggerates predictive value. Companies advertise “know your Alzheimer’s risk” or “take control of your brain health future,” implying that a single test captures someone’s actual risk. These tests typically report APOE genotype, tau levels, phosphorylated tau (p-tau), or polygenic scores with minimal contextual explanation.
A consumer receives a report saying “elevated risk” without understanding that elevated risk across millions of people means some will never develop cognitive impairment. Marketing materials routinely recommend expensive supplements, cognitive training programs, or medical monitoring based on the risk score, creating financial incentives for companies to amplify risk perception. A test that costs $500 becomes a revenue stream for supplement sales, brain-training subscriptions, and unnecessary clinic visits. The marketing also feeds into what’s called “disease creep,” where normal aging or minor cognitive changes are reframed as the beginning of Alzheimer’s disease in someone with a high risk score.
How Can Patients and Clinicians Use Risk Scores Responsibly?
Responsible use of Alzheimer’s risk scores requires understanding what they measure and what they don’t. A risk score should never stand alone as a clinical decision point. It’s one data point in a comprehensive assessment that includes cognitive testing, functional history, family history, imaging, and biomarker confirmation. A high-risk polygenic score in an asymptomatic 50-year-old does not warrant a diagnosis, medication, or life-limiting decisions.
It warrants monitoring and discussion about modifiable risk factors. For clinicians, the key is explaining probability and uncertainty clearly. Instead of “you have a 60% chance of Alzheimer’s,” effective communication sounds like: “This score shows a higher statistical risk, which means we should monitor you closely and focus on evidence-based prevention strategies like cardiovascular health, cognitive engagement, and sleep. But many people with this risk level never develop disease.” Patients need to know that risk scores are not destiny. For consumers considering direct-to-consumer testing, the rule is to discuss results with a neurologist or geriatrician before making any medical, financial, or life decisions.
What Are the Known Harms of False Positives and Psychological Burden?
Overdiagnosis in cognitive screening has reached crisis levels in some populations, and risk scores amplify this problem. A person with a high-risk score receives a cognitive screening test, performs normally, but is told “you’re at high risk, so let’s monitor you closely” or “you might be showing early signs.” Repeated appointments, frequent testing, and framing themselves as pre-diseased creates iatrogenic harm—illness caused by the healthcare encounter itself, not the underlying condition. The psychological burden is measurable.
Studies of people who received genetic testing for Alzheimer’s risk show increased anxiety scores, sleep disruption, and depressive symptoms even 12 months later. Some people become hypervigilant to normal aging (forgetting a name, misplacing keys) and catastrophize these events as disease. Others avoid social engagement, reporting a sense of hopelessness. For a condition that may not develop for decades, if at all, this psychological cost is often not weighed against any actual clinical benefit.
How Do Equity and Access Issues Amplify Misuse?
Alzheimer’s risk scores exacerbate existing health disparities because the science was built unequally. Polygenic risk scores are known to have reduced accuracy in non-European populations, yet these populations often face systemic barriers to preventive healthcare and specialist access. A Latino patient with a high-risk score may lack access to a neurologist to properly interpret it, leading to anxiety without actionable guidance. Meanwhile, a wealthy White patient with the same score receives counseling, specialist oversight, and access to clinical trials.
The Genetic Information Nondiscrimination Act (GINA) is also toothless for Alzheimer’s risk scores because it was written before these tools existed. GINA explicitly protects against genetic discrimination in health insurance and employment, but the law’s language predates polygenic scoring and doesn’t clearly cover composite risk models. Insurance companies exploit this gray area, requesting “health history” that includes genetic testing, then using risk scores to deny coverage under the guise of underwriting, not genetic discrimination. Enforcement is slow and expensive for individuals to pursue.
Where Are Safeguards Failing, and What Needs to Change?
Regulatory oversight of direct-to-consumer Alzheimer’s tests is minimal. The FDA does not require clinical validation of Alzheimer’s risk scores sold directly to consumers; these tests often launch with testimonials and marketing claims but no peer-reviewed evidence of accuracy in the populations that buy them. Insurance companies self-regulate their use of genetic data, which is to say they don’t regulate it meaningfully. Professional guidelines from the American Academy of Neurology and the Alzheimer’s Association recommend against using any single genetic or biomarker test to diagnose Alzheimer’s or predict future risk in asymptomatic people, yet these recommendations are not enforced and are widely ignored.
Clinician education is inadequate. Many primary care doctors and geriatricians have not been trained to interpret polygenic risk scores or explain them to patients. They receive marketing materials from test companies claiming clinical utility, and absent training, they accept these claims at face value. The International Early Alzheimer’s Disease Initiative (IEAD) and similar research programs fuel enthusiasm for identifying “at-risk” individuals, but the gap between research populations and clinical practice is vast. People identified as research subjects with biomarker evidence of early pathology are not equivalent to asymptomatic community members with a high genetic risk score, but this distinction is routinely lost in clinical and consumer messaging.
- —
